CN103772312B - 抗炎症的2-羰基噻唑和2-羰基恶唑 - Google Patents

抗炎症的2-羰基噻唑和2-羰基恶唑 Download PDF

Info

Publication number
CN103772312B
CN103772312B CN201310675185.1A CN201310675185A CN103772312B CN 103772312 B CN103772312 B CN 103772312B CN 201310675185 A CN201310675185 A CN 201310675185A CN 103772312 B CN103772312 B CN 103772312B
Authority
CN
China
Prior art keywords
alkyl
nmr
cdcl
group
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310675185.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103772312A (zh
Inventor
乔治·考考陶斯
白利特·约翰森
维多利亚·玛格丽奥蒂
迈克尔·特萨科斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coegin Pharma AS
Original Assignee
Avexxin AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avexxin AS filed Critical Avexxin AS
Publication of CN103772312A publication Critical patent/CN103772312A/zh
Application granted granted Critical
Publication of CN103772312B publication Critical patent/CN103772312B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201310675185.1A 2009-10-02 2010-10-01 抗炎症的2-羰基噻唑和2-羰基恶唑 Expired - Fee Related CN103772312B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24833809P 2009-10-02 2009-10-02
US61/248338 2009-10-02
CN201080056033.8A CN102647984B (zh) 2009-10-02 2010-10-01 抗炎症的2-羰基噻唑和2-羰基恶唑

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080056033.8A Division CN102647984B (zh) 2009-10-02 2010-10-01 抗炎症的2-羰基噻唑和2-羰基恶唑

Publications (2)

Publication Number Publication Date
CN103772312A CN103772312A (zh) 2014-05-07
CN103772312B true CN103772312B (zh) 2016-08-17

Family

ID=43221889

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201510086534.5A Expired - Fee Related CN104892542B (zh) 2009-10-02 2010-10-01 抗炎症的2‑羰基噻唑和2‑羰基恶唑
CN201080056033.8A Expired - Fee Related CN102647984B (zh) 2009-10-02 2010-10-01 抗炎症的2-羰基噻唑和2-羰基恶唑
CN201310675185.1A Expired - Fee Related CN103772312B (zh) 2009-10-02 2010-10-01 抗炎症的2-羰基噻唑和2-羰基恶唑

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201510086534.5A Expired - Fee Related CN104892542B (zh) 2009-10-02 2010-10-01 抗炎症的2‑羰基噻唑和2‑羰基恶唑
CN201080056033.8A Expired - Fee Related CN102647984B (zh) 2009-10-02 2010-10-01 抗炎症的2-羰基噻唑和2-羰基恶唑

Country Status (11)

Country Link
US (2) US9597318B2 (enExample)
EP (2) EP3431084A1 (enExample)
JP (1) JP6012468B2 (enExample)
KR (4) KR101907535B1 (enExample)
CN (3) CN104892542B (enExample)
AU (1) AU2010302584B2 (enExample)
CA (1) CA2782797C (enExample)
DK (1) DK2482815T3 (enExample)
IN (1) IN2012DN02982A (enExample)
NO (1) NO2482815T3 (enExample)
WO (1) WO2011039365A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104892542B (zh) 2009-10-02 2018-01-26 埃维克辛公司 抗炎症的2‑羰基噻唑和2‑羰基恶唑
GB201205394D0 (en) 2012-03-27 2012-05-09 Adlens Ltd Improvements in or relating to deformable non-round membrane assemblies
GB201221329D0 (en) 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
KR102268357B1 (ko) * 2013-01-29 2021-06-23 아벡신 에이에스 항염증성 및 항종양성 2-옥소티아졸 및 2-옥소티오펜 화합물
GB201307331D0 (en) * 2013-04-23 2013-05-29 Norwegian Univ Sci & Tech Ntnu Compound
GB201409363D0 (en) 2014-05-27 2014-07-09 Avexxin As Skin cancer treatment
GB201413695D0 (en) * 2014-08-01 2014-09-17 Avexxin As Compound
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
GB2550363A (en) * 2016-05-16 2017-11-22 Avexxin As Compound
AU2017329957B2 (en) 2016-09-21 2020-05-07 Avexxin As Pharmaceutical composition
AU2017353448B2 (en) * 2016-11-04 2020-08-27 Avexxin As Combination therapy comprising a thiazole and a corticosteroid to treat skin conditions
EP3534956A1 (en) * 2016-11-04 2019-09-11 Avexxin AS Combination therapy comprising a thiazole and a secosteroid to treat skin conditions
JP7169584B2 (ja) * 2018-01-30 2022-11-11 公立大学法人横浜市立大学 オーキシン生合成阻害活性を有する新規化合物、その製造方法及びその用途
GB201806663D0 (en) 2018-04-24 2018-06-06 Avexxin As 2-Oxothiazole compositions for treatment of fibrotic disease
EP3677259A1 (en) * 2019-01-07 2020-07-08 Mosaiques Diagnostics And Therapeutics AG Use of arachidonyl trifluoromethyl ketone
GB202117609D0 (en) 2021-12-06 2022-01-19 Coegin Pharma Ab 2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia
CN115028597B (zh) * 2022-04-29 2024-03-26 闽都创新实验室 一种tempo连续脱氢环化制备苯并恶唑类衍生物的方法和应用
WO2025125241A1 (en) 2023-12-15 2025-06-19 Coegin Pharma Ab Pharmaceutical composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569655A (en) * 1993-09-14 1996-10-29 Sterling Winthrop Inc. Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
WO1996036617A1 (en) * 1995-05-19 1996-11-21 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
WO2000034254A1 (en) * 1998-12-04 2000-06-15 Astrazeneca Ab Novel compounds
US6462054B1 (en) * 2000-03-27 2002-10-08 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
WO2006016218A1 (en) * 2004-08-03 2006-02-16 Pfizer Japan Inc. Aryl or heteroaryl carbonyl derivatives derivatives useful as vanilloid receptor 1 (vr1) antagonists

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2062868B1 (enExample) * 1969-09-15 1973-08-10 Innothera Lab Sa
US3894152A (en) * 1969-09-15 1975-07-08 Innothera Lab Sa Use of (thienyl-3)(3-N-morpholine-propy)ketone
DE2063901A1 (en) 1970-12-28 1972-07-20 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Phenylalkylaminoalkylthiazoles - as antiphlogistics
US5177215A (en) 1984-11-12 1993-01-05 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclic compounds and pharmaceutical use thereof
PH22520A (en) 1984-11-12 1988-10-17 Yamanouchi Pharma Co Ltd Heterocyclic compounds having 4-lover alkyl-3-hydroxy-2-lower alkyl phenoxy-lower alkylene-y-group, and process of producing them
JPS62142168A (ja) 1985-10-16 1987-06-25 Mitsubishi Chem Ind Ltd チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤
ZA894913B (en) 1988-07-12 1990-03-28 Ici Pharma Heterocyclic compounds
US5272986A (en) 1991-05-13 1993-12-28 British Gas Plc Towing swivel for pipe inspection or other vehicle
TW263504B (enExample) * 1991-10-03 1995-11-21 Pfizer
GB9211706D0 (en) 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5273986A (en) 1992-07-02 1993-12-28 Hoffmann-La Roche Inc. Cycloalkylthiazoles
US5268395A (en) 1992-10-13 1993-12-07 Martin Marietta Energy Systems, Inc. Microcellular carbon foam and method
JP3345476B2 (ja) * 1993-05-18 2002-11-18 株式会社東芝 有機非線形光学材料
EP0772606A1 (en) 1994-07-27 1997-05-14 G.D. SEARLE & CO. Substituted thiazoles for the treatment of inflammation
US6214994B1 (en) * 1997-04-21 2001-04-10 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1′-yl propanones
US5693804A (en) * 1994-11-17 1997-12-02 Molecular Geriatrics Corporation Substituted 1-aryl-3-piperazin-1'-yl propanones
US5658909A (en) * 1994-11-17 1997-08-19 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1'-yl propanones to treat Alzheimer's Disease
TW438786B (en) 1995-03-28 2001-06-07 Nippon Zoki Pharmaceutical Co Novel benzothiazole derivatives
CA2224121A1 (en) * 1995-06-06 1996-12-12 Donna Kaye Wilson Stereoselective method for synthesizing dolaphenine
DE19638408A1 (de) * 1996-09-19 1998-03-26 Merckle Gmbh 1-Substituierte 3-Acyl-4,5-dimethylpyrrol-2-carbonsäuren und 3-Acylindol-2-carbonsäuren sowie ihre Derivate als Hemmstoffe der cytosolischen Phospholipase A¶2¶
US6414145B1 (en) * 1997-01-29 2002-07-02 Zeneca Limited Imidazolyl compounds as inhibitors of farnesyl-protein tranferase
EP0867437B1 (en) 1997-03-14 2002-11-13 Koninklijke Philips Electronics N.V. "Method of preparing a thiophene-containing or furan -containing conjugated compound and precursor compound used therein".
EP1140791A4 (en) * 1997-09-23 2001-10-10 Bristol Myers Squibb Co SELECTIVE CPLA 2 INHIBITORS
JPH11255700A (ja) 1998-03-12 1999-09-21 Taiho Ind Co Ltd アセチルアセトン系金属錯体及びその合成法、並びにそれを用いた有機多層型エレクトロルミネッセンス素子
CA2339970A1 (en) 1998-08-11 2000-02-24 Nihon Bayer Agrochem K.K. Nematicidal pyrazoles
CA2370500A1 (en) 1999-06-25 2001-01-04 Lekhanh O. Tran 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof
JP2001240593A (ja) * 1999-10-12 2001-09-04 Japan Tobacco Inc 高トリグリセリド血症治療薬及び抗肥満薬
CN1429224A (zh) 2000-05-18 2003-07-09 第一制药株式会社 新颖苯并噻吩衍生物
US20020052373A1 (en) * 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
US6734207B2 (en) * 2001-04-20 2004-05-11 Parker Hughes Institute Cytotoxic compounds
US7056917B2 (en) 2001-04-26 2006-06-06 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
WO2003051194A1 (en) 2001-12-18 2003-06-26 3Cpm Company Endoscopic measurement of myoelectrical activity from intra-abdominal organs
GB0202002D0 (en) * 2002-01-29 2002-03-13 Leiv Eiriksson Nyotek A S Use
EP1549600A1 (en) 2002-07-27 2005-07-06 AstraZeneca AB Ketones
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
US6930391B2 (en) 2002-08-27 2005-08-16 Intel Corporation Method for alloy-electroplating group IB metals with refractory metals for interconnections
DE60327640D1 (enExample) * 2002-10-08 2009-06-25 Scripps Research Inst
GB2394894B (en) 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
WO2004041264A1 (en) 2002-11-07 2004-05-21 Astrazeneca Ab 2-oxo-ethanesulfonamide derivates
WO2005028465A1 (ja) 2003-09-18 2005-03-31 Tokuyama Corporation クロメン化合物
SA04250288B1 (ar) 2003-09-19 2008-07-19 سولفاي فارماسوتيكالز بي . في مشتقات ثيازول thiazole كمعدلات لمستقبل المكونات الكيميائية للقنب cannabinoid
JP4226438B2 (ja) 2003-10-23 2009-02-18 エヌ・ティ・ティ・コムウェア株式会社 パック装置およびセンステーブル装置、ならびに移動軌跡算出方法、移動軌跡算出プログラム、その記録媒体
US20050137243A1 (en) 2003-12-23 2005-06-23 Souers Andrew J. Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
JP2005343889A (ja) * 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
BRPI0511250A (pt) 2004-05-17 2007-11-27 Otsuka Pharma Co Ltd composto de tiazol e uso deste
US7178364B2 (en) 2004-07-22 2007-02-20 Shapiro Kristen M Personal adornment
KR20060058632A (ko) * 2004-11-25 2006-05-30 주식회사 엘지생명과학 ＰＰＡＲ ｇａｍｍａ와 ＰＰＡＲ ａｌｐｈａ의 활성을항진시키는 신규 화합물, 그것의 제조방법, 및 그것을함유한 약제 조성물
WO2007061862A2 (en) * 2005-11-18 2007-05-31 Janssen Pharmaceutica N.V. 2-keto-oxazoles as modulators of fatty acid amide hydrolase
ATE525374T1 (de) 2005-12-13 2011-10-15 Incyte Corp Heteroarylsubstituierte pyrroloä2,3-büpyridine und pyrroloä2,3-büpyrimidine als januskinaseinhibitoren
US7915270B2 (en) * 2006-02-17 2011-03-29 The Scripps Research Institute Oxazole ketones as modulators of fatty acid amide hydrolase
EP2051964A4 (en) * 2006-07-28 2012-03-07 Univ Connecticut INHIBITORS OF FATTY ACID AMIDHYDROLASE
WO2008105408A1 (ja) * 2007-02-26 2008-09-04 Santen Pharmaceutical Co., Ltd. ウレイド基とアミノカルボニル基を置換基として有する新規ピロール誘導体
JP5138708B2 (ja) * 2007-03-05 2013-02-06 エフ．ホフマン−ラ ロシュ アーゲー オレキシンアンタゴニストとしてのアミノアミド
EP2161997A4 (en) * 2007-05-31 2011-04-06 Scripps Research Inst TRICYCLIC INHIBITORS OF FATTY ACID AMIDHYDROLASE
CN104892542B (zh) 2009-10-02 2018-01-26 埃维克辛公司 抗炎症的2‑羰基噻唑和2‑羰基恶唑
WO2012070420A1 (ja) 2010-11-22 2012-05-31 日立化成工業株式会社 希土類金属錯体
KR102268357B1 (ko) * 2013-01-29 2021-06-23 아벡신 에이에스 항염증성 및 항종양성 2-옥소티아졸 및 2-옥소티오펜 화합물
GB201413695D0 (en) * 2014-08-01 2014-09-17 Avexxin As Compound

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569655A (en) * 1993-09-14 1996-10-29 Sterling Winthrop Inc. Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
WO1996036617A1 (en) * 1995-05-19 1996-11-21 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
WO2000034254A1 (en) * 1998-12-04 2000-06-15 Astrazeneca Ab Novel compounds
US6462054B1 (en) * 2000-03-27 2002-10-08 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
WO2006016218A1 (en) * 2004-08-03 2006-02-16 Pfizer Japan Inc. Aryl or heteroaryl carbonyl derivatives derivatives useful as vanilloid receptor 1 (vr1) antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Optimization of the Central Heterocycle of α-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase;Joie Garfunkle，等;《Journal of Medicinal Chemistry》;20080716;第51卷(第15期);4392-4403 *

Also Published As

Publication number Publication date
US9597318B2 (en) 2017-03-21
KR20180114228A (ko) 2018-10-17
AU2010302584A1 (en) 2012-05-24
HK1210157A1 (en) 2016-04-15
IN2012DN02982A (enExample) 2015-07-31
JP2013506639A (ja) 2013-02-28
WO2011039365A1 (en) 2011-04-07
CN104892542A (zh) 2015-09-09
KR20120089701A (ko) 2012-08-13
AU2010302584B2 (en) 2015-09-10
KR20170038941A (ko) 2017-04-07
CN104892542B (zh) 2018-01-26
EP2482815A1 (en) 2012-08-08
HK1197551A1 (zh) 2015-01-23
DK2482815T3 (en) 2018-06-06
US20170166539A1 (en) 2017-06-15
JP6012468B2 (ja) 2016-10-25
NO2482815T3 (enExample) 2018-09-29
KR20190082985A (ko) 2019-07-10
US20110136879A1 (en) 2011-06-09
KR101997163B1 (ko) 2019-07-08
CN102647984A (zh) 2012-08-22
CN103772312A (zh) 2014-05-07
KR101907535B1 (ko) 2018-10-15
CA2782797A1 (en) 2011-04-07
CN102647984B (zh) 2015-03-25
EP3431084A1 (en) 2019-01-23
EP2482815B1 (en) 2018-05-02
CA2782797C (en) 2018-08-07
US10370344B2 (en) 2019-08-06

Similar Documents

Publication Publication Date Title
CN103772312B (zh) 抗炎症的2-羰基噻唑和2-羰基恶唑
CN1372548A (zh) 杂环化合物及其医药用途
AU2003282754A1 (en) Novel heterocyclic analogs of diphenylethylene compounds
EP1525193B1 (fr) Derives d'acylaminothiazole et leur utilisation comme inhibiteurs de beta-amyloide
US20040186299A1 (en) Novel heterocyclic analogs of diphenylethylene compounds
AU2015268638B2 (en) Anti inflammatory 2-oxothiazoles and 2-oxooxazoles
JP2007126454A (ja) アニリド誘導体
IE904522A1 (en) Pharmacologically Active Amide Carboxylate Derivatives
JP4550353B2 (ja) 造血器型プロスタグランジンｄ２合成酵素阻害剤
WO2005084658A1 (en) Derivatives of actarit and their therapeutic use
HK1197551B (en) Anti inflammatory 2-oxothiazoles and 2-oxooxazoles
HK1210157B (en) Anti inflammatory 2-oxothiazoles and 2-oxooxazoles
FR2850380A1 (fr) Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
JP2005508317A (ja) ヒドロキシエイコセン酸類似体
JP2008533122A (ja) 新規なチロシン誘導体
EP1709041A1 (fr) Derives d'acylaminothiazole, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1197551

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1197551

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160817